First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

Lucia TaramassoA Di BiagioF MaggioloA TavelliS Lo CaputoS BonoraM ZaccarelliP CaramelloA CostantiniC ViscoliA d'Arminio MonforteA Cozzi-Leprinull null

Published in: HIV medicine (2018)

In our nonrandomized comparison, RPV was better tolerated, less toxic and showed longer durability than EFV, without a significant difference in rates of discontinuation because of failures.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
human immunodeficiency virus
hiv positive
hiv aids